July 25 Biogen Idec Inc on Thursday
reported sales of its new multiple sclerosis drug Tecfidera that
blew away initial Wall Street estimates, confirming an extremely
strong launch for a medicine expected to dominate the market for
In its first quarter on the market, Tecfidera had sales of
$192 million, including inventory stocking. Biogen said about
$110 million of the total represented underlying patient demand.
Analysts looked for about $66 million for the quarter.
Tecfidera is widely considered to be Biogen's most important
future growth driver, with analysts targeting eventual peak
sales in excess of $3 billion.
(Reporting by Bill Berkrot; Editing by Jeffrey Benkoe)